HomeHealth & FitnessManufacturer: Approval for Phase I trial of dengue vaccine

Manufacturer: Approval for Phase I trial of dengue vaccine

The Indian Immunologicals Limited (IIL), the country’s leading vaccine maker, has got the nod for the Phase I trial of dengue vaccine, a top official said on Tuesday.

talking to Indian Express On the sidelines of the World Dairy Summit in Greater Noida, Dr K Anand Kumar, Managing Director, IIL said: “We have now got the Phase-I (trial) permission for Dengue (vaccine). We got permission yesterday. As of now (in India) there is no vaccine for dengue. This will be a huge milestone. We have completed all animal testing and now we are being allowed to do human trials.”

Kumar said IIL is developing the dengue vaccine in collaboration with the US-based National Institutes of Health (NIH). “They provided us with the virus,” he said.

When asked when the Phase-I trial would start, Kumar said, “Centers for testing have already been identified.” He expressed the hope that the vaccine will be launched in the next two years.

Official records show that there are two other dengue vaccines – being developed by Panacea Biotech Ltd and Sanofi India Pvt Ltd. Both have got permission for clinical trials. Panacea Biotec Limited has completed Phase-I and Phase-II trials.

Sanofi India Private Limited’s vaccine has already been approved in the US; It has started testing in India.

According to the National Center for Vector Borne Disease Control (NCVBDC), there were 1,93,245 dengue cases and 346 deaths across the country last year.

IIL, a subsidiary of the National Dairy Development Board, manufactures animal and human vaccines. It is one of two suppliers of the goat pox vaccine, which is currently being administered to prevent lumpy skin disease in cattle.

Kumar said IIL has increased production of goat pox vaccine from 10 lakh doses in July to around 10 million doses in August this year. Earlier, IIL used to supply 2-3 million goat pox vaccines a year, Kumar said, adding that the price of the vaccine is Rs 5 per dose.

When asked about the indigenous lumpy skin vaccine developed by the Indian Council of Agricultural Research (ICAR), Kumar said, “We are in talks with Agrinovate India. Tomorrow is the first meeting. We will ask them about vaccine data and other relevant information.” Agrinovate India is the commercialization arm for products and technologies developed by ICAR institutes.

Two ICAR institutes – National Research Center (NRCE) at Hisar (Haryana) and Indian Veterinary Research Institute (IVRI) at Izzatnagar (UP) have jointly developed Lumpy-Pro Vaccine Vaccine.

According to animal husbandry department sources, till September 11 this year, 16.42 lakh cattle were affected by the lumpy skin disease in 197 districts of 13 states across the country. As of 11 September, about 75,000 cattle deaths were reported due to the disease; Sources said 9.96 lakh cattle were recovered, while 5.5 lakh were active cases. Till September 11, a total of 1.10 crore vaccine doses have been given.
Sources said.

Author
Authorhttps://searchnews.in
Hello Friends, My Name is Raushan Kumar. I am a Part-Time Blogger and Student. I am author of https://searchnews.in . We're dedicated to providing you the best of News, with a focus on Business, Health, Lifestyle, World, Tech, India, Gadget.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

- Advertisment -